Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urea SCHEMBL8887503 | 0.89 | TRPA1 (0.40) | TRPA1MAPK1ATMHSP90AA1 | |
| SCHEMBL11830486 | 0.89 | TRPA1 (0.35) | TRPA1KDM4EMAPK1ATMHSP90AA1 | |
| SCHEMBL9268163 | 0.86 | TRPA1 (0.38) | TRPA1ATMCYP1A2CYP2D6 | |
| SCHEMBL5944362 | 0.71 | ALDH1A1 (0.44) | TRPA1KDM4E | |
| SCHEMBL8538005 | 0.71 | NPC1 (0.36) | KDM4EMAPK1ATM | |
| SCHEMBL4501496 | 0.68 | TYMS (0.35) | TRPA1KDM4EMAPK1ATMCYP1A2 | |
| SCHEMBL10483802 | 0.66 | MYC (0.42) | KDM4E | |
| SCHEMBL5841466 | 0.65 | DRD2 (0.37) | TRPA1KDM4EMAPK1ATMHSP90AA1 | |
| SCHEMBL244606 | 0.65 | KDM4E (0.37) | TRPA1KDM4E | |
| SCHEMBL29757278 | 0.64 | KDM4E (0.36) | TRPA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1668 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026042047-A1 | COMPOSITIONS AND ARTICLES COMPRISING REVERSIBLE COMPLEXES OF CROSSLINKED CARRAGEENAN | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-120025756-A | Degradable printing adhesive tape and preparation method thereof | 浙江睿麟科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-222342036-U | Dibenzoxazelone heterocyclic derivative preparation device | 江苏兢业制药有限公司 | 2025-01-14 | — | — | CN | claimed |
| US-20240277729-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | BOEHRINGER INGELHEIM INT (DE) | 2024-08-22 | — | — | US | claimed |
| CN-117343094-A | Light-emitting element and nitrogen-containing compound for light-emitting element | 三星显示有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-116854643-A | Synthesis method of dibenzodiazepine or oxyazepine compound | 中山大学 | 2023-10-10 | — | — | CN | claimed |
| CN-114752508-B | Aspergillus polypolypolyvidone MNP-2 and application thereof in synthesis of dibenzooxazepine compounds | 浙江工业大学 | 2023-09-05 | — | — | CN | claimed |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | SYNEDGEN, INC. (US) | 2023-08-08 | — | — | US | claimed |
| CN-113072518-B | Dibenzo azepine derivative and preparation method thereof | 上海兆维科技发展有限公司 | 2022-10-21 | — | — | CN | claimed |
| EP-0386117-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-09-12 | — | — | EP | claimed |
| WO-1990004387-A2 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-03 | — | — | WO | claimed |
| US-4886795-A | Treatment and prevention of retinal edema with dopaminergic antagonists | SCHACHAR RONALD A (US) | 1989-12-12 | — | — | US | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |
| EP-0040860-B1 | DIBENZOXAZEPINE DERIVATIVE, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 1984-03-14 | — | — | EP | claimed |
| US-4435391-A | ANTICOAGULANTS, ANTILIPEMIC AGENTS, 6- OR 8-CARBOXY SUBSTITUTED | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1984-03-06 | — | — | US | claimed |
| EP-0012385-B1 | DIBENZ(B,F)(1,4)OXAZEPINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | Chugai Seiyaku Kabushiki Kaisha (JP) | 1983-02-16 | — | — | EP | claimed |
| EP-0040860-A1 | Dibenzoxazepine derivative, process for preparing the same and pharmaceutical composition comprising the same | Chugai Seiyaku Kabushiki Kaisha (JP) | 1981-12-02 | — | — | EP | claimed |
| US-4290953-A | ANTICHOLESTEROL AGENT, ANTILIPEMIC AGENT AND ANTICOAGULANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1981-09-22 | — | — | US | claimed |
| EP-0012385-A1 | Dibenz(b,f)(1,4)oxazepine derivatives, process for their preparation and pharmaceutical compositions | Chugai Seiyaku Kabushiki Kaisha (JP) | 1980-06-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277729-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | SLC5A2, SLC5A1, SLC6A2 | TRPA1 2274/4885KDM4E 2651/4885MAPK1 1767/4885 |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | CHIA, MMP8, CHIT1 | TRPA1 1546/4885KDM4E 3991/4885MAPK1 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.